Search
Search
EURETINA: 2025
Charles C. Wykoff, MD, PhD
Show Description +
Dr. Wykoff explores interim data from a phase 1b study of KSI-101 (Kodiak Sciences) for patients with macular edema secondary to inflammation. KSI-101 is a bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor.
Posted: 9/18/2025
Charles C. Wykoff, MD, PhD
Dr. Wykoff explores interim data from a phase 1b study of KSI-101 (Kodiak Sciences) for patients with macular edema secondary to inflammation. KSI-101 is a bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor.
Posted: 9/18/2025
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of EURETINA: 2025.
Please log in to leave a comment.